Stryker Corporation (SYK)

SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.

I reiterate a Hold rating on Stryker Corporation, with a fair value of $382 per share, despite recent strong quarterly results. Stryker's Mako installations and utilization remain robust, and upcoming...

Stryker continues to outperform peers with strong revenue growth, margin expansion, and successful product innovation. Recent quarterly results beat expectations, driven by robust performance across t...

Stryker (SYK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors with an interest in Medical - Products stocks have likely encountered both Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RL, SYK, RGLD and ADSK hold promise.

Here is how Stryker (SYK) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Stryker (SYK) Q2 Revenue Jumps 11%

The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.